他汀类药物不会损害血脂异常成人中强度运动期间全身脂肪氧化

Q4 Health Professions

Swiss Sports and Exercise Medicine Pub Date : 2018-10-08 DOI:10.26644/EM.2018.012

M. A. Matuszek, R. Grant

{"title":"他汀类药物不会损害血脂异常成人中强度运动期间全身脂肪氧化","authors":"M. A. Matuszek, R. Grant","doi":"10.26644/EM.2018.012","DOIUrl":null,"url":null,"abstract":"Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for atorvastatin and 34 for rosuvastatin [2]. Physiologically, these drugs inhibit liver enzyme HMGCoA reductase, blocking cholesterol synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical activity are valuable contributors to maintaining healthy blood lipids, with exercise improving cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular disease, stroke, type 2 diabetes mellitus Research Article Exercise Medicine Open Access eISSN: 2508-9056","PeriodicalId":36798,"journal":{"name":"Swiss Sports and Exercise Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Statins Do Not Impair Whole-body Fat Oxidation During Moderate-intensity Exercise in Dyslipidemic Adults\",\"authors\":\"M. A. Matuszek, R. Grant\",\"doi\":\"10.26644/EM.2018.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for atorvastatin and 34 for rosuvastatin [2]. Physiologically, these drugs inhibit liver enzyme HMGCoA reductase, blocking cholesterol synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical activity are valuable contributors to maintaining healthy blood lipids, with exercise improving cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular disease, stroke, type 2 diabetes mellitus Research Article Exercise Medicine Open Access eISSN: 2508-9056\",\"PeriodicalId\":36798,\"journal\":{\"name\":\"Swiss Sports and Exercise Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Swiss Sports and Exercise Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26644/EM.2018.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss Sports and Exercise Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26644/EM.2018.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 1

摘要

降脂药是世界范围内(包括欧洲和美国)最常见的补贴处方药之一。2016年，阿托伐他汀和辛伐他汀在美国排名第1位和第7位[1]。同年，在澳大利亚，阿托伐他汀和瑞舒伐他汀分别排在第1位和第3位，每天服用阿托伐他汀的澳大利亚人每千人中有53人服用阿托伐他汀，34人服用瑞舒伐他汀[2]。生理上，这些药物抑制肝酶HMGCoA还原酶，阻断胆固醇合成。它们在心血管疾病和全因死亡率的二级预防中被认为是有效的[3]。然而，现在已经确定，健康的饮食和有规律的体育活动对保持健康的血脂有重要的贡献，锻炼可以改善心血管健康;降低全因死亡率和冠心病、心血管疾病、中风、2型糖尿病的风险

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Statins Do Not Impair Whole-body Fat Oxidation During Moderate-intensity Exercise in Dyslipidemic Adults

Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for atorvastatin and 34 for rosuvastatin [2]. Physiologically, these drugs inhibit liver enzyme HMGCoA reductase, blocking cholesterol synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical activity are valuable contributors to maintaining healthy blood lipids, with exercise improving cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular disease, stroke, type 2 diabetes mellitus Research Article Exercise Medicine Open Access eISSN: 2508-9056

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Swiss Sports and Exercise Medicine Health Professions-Physical Therapy, Sports Therapy and Rehabilitation

CiteScore

0.20

自引率

0.00%

发文量